CNBX 8-K
CNBX Pharmaceuticals Inc. (CNBX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices and Zip Code)
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
CNBX Pharmaceuticals’ (the “Company”) Chief Technology Officer Dr. Eyal Ballan has resigned his position as CTO and his employment with the Company has ended effective July 20th, 2022. Dr. Sanja Goldberg was appointed as the Company’s new Chief Technology Officer on July 24th, 2022.
Dr. Goldberg, 46, has held several Senior Researcher positions at Israel’s largest hospital, Sheba Medical Center’s Cancer Research Lab and Regenerative Research Lab. Additionally she has had several Executive positions, including at Compugen and at TaGeza Biopharma where she was VP of Research and Development. Dr. Goldberg obtained her Ph.D. in Cell Biology from the Department of Cell Biology and Genetics, Erasmus MC, Rotterdam, the Netherlands, in 2009, and has since led cutting edge science in her positions related to cancer and early-stage drug discovery activities.
| 2 |
SIGNATURE
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CNBX PHARMACEUTICALS INC. | |
| Date: July 25, 2022 | By: /s/ Eyal Barad |
| Eyal Barad | |
| Chief Executive Officer |
| 3 |